VISTAGEN THERAPEUTICS, INC. Deferred Revenue (Non-Current)
VISTAGEN THERAPEUTICS, INC. (VTGN) had Deferred Revenue (Non-Current) of $2.31 million as of 2023-03-31, per its 10-K filed 2023-06-28.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredRevenueNoncurrent · last filed 2023-06-28
- 2023-03-31: Deferred Revenue, Noncurrent $2.31M.
- 2022-03-31: Deferred Revenue, Noncurrent $1.56M.
- 2021-06-30: Deferred Revenue, Noncurrent $2.14M.
- 2021-03-31: Deferred Revenue, Noncurrent $2.49M.
| Period end | Deferred Revenue, Noncurrent |
|---|---|
| 2023-03-31 | $2.31M 10-K · filed 2023-06-28 |
| 2022-03-31 | $1.56M 10-K · filed 2023-06-28 |
| 2021-06-30 | $2.14M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $2.49M 10-K · filed 2023-06-28 |
| 2020-12-31 | $3.11M 10-Q · filed 2021-02-11 |
| 2020-09-30 | $3.42M 10-Q · filed 2020-11-12 |
| 2020-03-31 | $0.00 10-K · filed 2021-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |